Japan's Pharma Companies Should Consolidate, Says Bayer Yakuhin Chairman
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's 1,270 pharmaceutical companies should consolidate to look more like the pharma industry in the U.S. or Germany, Bayer Yakuhin Chairman Norikazu Eiki said at the IBC Drug and Biologics conference in Tokyo Feb. 22
You may also be interested in...
Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview with PharmAsia News (Part 2 of 2)
Established in 1992 as the first contract clinical trial research organization in Japan, CMIC is now one of the largest Japanese CROs and currently employs more than 2,500 employees. The company operates in Japan, the United States, South Korea, Taiwan, Singapore and China. CMIC Corporate Officer Asia Development Moriaki Akasaki sat down with PharmAsia News' Japan bureau to give his perspective on the how the International Conference on Harmonization Good Clinical Practices agreements will affect Japan and other Asian countries. Japan, for the first time is beginning to accept clinical data from China and Koreain accordance with the ICH Regional Harmonization Initiative.
Battling Negative Image Of Generics In Japan (Part 2 of 2)
[Editor's note: This is part two of a two-part feature on obstacles in promoting generics in Japan. Part one, which explored negative connotations associated with with the term "generic," appeared in PharmAsia News, March 19, 2009.]
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).